• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconAllergan

Allergan

Page 5 of 6
Views of The Facebook Inc. Logo Ahead of Earnings
Tech
VW’s New Horror And Facebook 3Q–5 Things To Know Today
By Laura Lorenzetti and Geoffrey SmithNovember 4, 2015
Pfizer And AstraZeneca's Billion Dollar Battle
Finance
Pfizer-Allergan could be a super inversion deal
By Stephen GandelOctober 29, 2015
Pershing Square Capital Management LP Founder And Chief Executive Officer William "Bill" Ackman
Features
Ackman’s back and Allergan — 5 things to know today
By Tom Huddleston Jr. and Geoffrey SmithAugust 6, 2015
Brenton Saunders, David Pyott
Finance
From Actavis to Allergan: One pharma company’s wild dealmaking journey
By Stacy Jones, Kacy Burdette and Jen WiecznerJuly 30, 2015
A Teva Pharmaceutical Industries factory in Jerusalem, Israel.
Finance
The real reasons for the pharma merger boom
By Jen WiecznerJuly 28, 2015
Inside Teva Pharmaceuticals Headquarters
Commentary
Teva buys Allergan: 3 reasons why it’s a blockbuster deal
By S. KumarJuly 27, 2015
Actavis CEO Brenton Saunders and Allergan CEO David Pyotton pose together on the floor of the New York Stock Exchange
Finance
Allergan CEO: How to survive an activist attack
By Stephen GandelFebruary 12, 2015
IL: Corporations In Illinois
Finance
Fat Pharma: Pfizer-Hospira and the top 10 overpriced drug deals ever
By Jen WiecznerFebruary 6, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
Finance
After Allergan loss, is Valeant dumpster diving?
By Jen WiecznerJanuary 31, 2015
Key Speakers At The Stanford Institute For Economic Policy Research Forum
Leadership
Step aside Wall Street, small pharma CEO pay reaches for the sky
By Paul HodgsonJanuary 5, 2015
Activist investors: The best (and worst) performers of 2014
Finance
Activist investors: The best (and worst) performers of 2014
By Stephen GandelDecember 3, 2014
Actavis CEO Brenton Saunders and Allergan CEO David Pyotton pose together on the floor of the New York Stock Exchange
Finance
Allergan CEO hands Botox maker to lawyer instead of consultant
By Stephen GandelNovember 17, 2014
Botox
Finance
Actavis agrees to buy Botox-maker Allergan for $66 billion
By John KellNovember 17, 2014
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
Finance
Zoetis shares spike on reported Ackman stake purchase
By Tom Huddleston Jr.November 11, 2014
Did Bill Ackman just kill the poison pill?
Finance
Did Bill Ackman just kill the poison pill?
By Stephen GandelNovember 6, 2014
1
  • 2
  • 3
  • 4
  • 5
  • 6
6
Most Popular
Big Tech
As Big Tech showers employees with perks to win the talent war, Nvidia built a nearly $5 trillion company by making people pay for their own lunchplaceholder alt text
By Marco Quiroz-GutierrezJuly 1, 2026
Success
MacKenzie Scott alone accounted for one-third of America's $19.2 billion in megagifts last yearplaceholder alt text
By Sydney LakeJune 25, 2026
Newsletters
The Supreme Court's birthright citizenship ruling hands the U.S. economy a $7.7 trillion winplaceholder alt text
By Diane BradyJuly 1, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.